Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors

Bibliography

• Lötsch J, Doehring A, Mogil JS, et al. Functional genomics of pain in analgesic drug development and therapy. Pharmacol Ther 2013;139(1):60-70
   PubMed Web of Science ®Google Scholar
• Raffa RB. On subclasses of opioid analgesics. Curr Med Res Opin 2014;30(12):2579-84
   PubMed Web of Science ®Google Scholar
• Sałat K, Kowalczyk P, Gryzło B, et al. New investigational drugs for the treatment of neuropathic pain. Expert Opin Investig Drugs 2014;23(8):1093-104
   PubMed Web of Science ®Google Scholar
• Brederson JD, Kym PR, Szallasi A. Targeting TRP channels for pain relief. Eur J Pharmacol 2013;716:61-76
   PubMed Web of Science ®Google Scholar
• Trevisani M, Szallasi A. Targeting TRPV1: challenges and issues in pain management. Open Drug Discov J 2010;2:37-49
   Google Scholar
• Sałat K, Jakubowska A, Kulig K. Zucapsaicin for the treatment of neuropathic pain. Expert Opin Investig Drugs 2014;10:1433-40
   Google Scholar
• Ko MC, Woods JH, Fantegrossi WE, et al. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Pharmacol Ther 2014;141(3):283-99
   PubMedGoogle Scholar
• Lin AP, Ko MC. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci 2013;4(2):214-24
   PubMed Web of Science ®Google Scholar
• Linz K, Christoph T, Tzschentke TM, et al. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther 2014;349(3):535-48
   PubMed Web of Science ®Google Scholar
• Schröder W, Lambert DG, Ko MC, Koch T. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. Br J Pharmacol 2014;171(16):3777-800
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73
   PubMed Web of Science ®Google Scholar
• O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122(10 Suppl):S22-32
   PubMed Web of Science ®Google Scholar
• Lambert DG, Bird MF, Rowbotham DJ. Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth 2015;114(3):364-6
   PubMed Web of Science ®Google Scholar
• Witkin JM, Statnick MA, Rorick-Kehn LM, et al. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther 2014;141(3):283-99
   PubMed Web of Science ®Google Scholar
• Chiou LC, Liao YY, Fan PC, et al. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr Drug Targets 2007;8(1):117-35
   PubMed Web of Science ®Google Scholar
• Gear RW, Bogen O, Ferrari LF, et al. NOP receptor mediates anti-analgesia induced by agonist-antagonist opioids. Neuroscience 2014;257:139-48
   PubMed Web of Science ®Google Scholar
• Khroyan TV, Polgar WE, Jiang F, et al. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/µ-opioid receptor agonists. J Pharmacol Exp Ther 2009;331(3):946-53
   PubMed Web of Science ®Google Scholar
• Cremeans CM, Gruley E, Kyle DJ, Ko MC. Roles of mu-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates. J Pharmacol Exp Ther 2012;343(1):72-8
   PubMed Web of Science ®Google Scholar
• Gavioli EC, Calo’ G. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs. Pharmacol Ther 2013;140(1):10-25
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Liao YY, Guerrini R, et al. Quantitative study of [(pF)Phe4,Arg14,Lys15]nociceptin/orphanin FQ-NH2 (UFP-102) at NOP receptors in rat periaqueductal gray slices. Eur J Pharmacol 2008;579(1-3):110-15
   PubMed Web of Science ®Google Scholar
• Chiou LC, Chuang KC, Wichmann J, Adam G. Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaqueductal gray slices. J Pharmacol Exp Ther 2004;311(2):645-51
   PubMed Web of Science ®Google Scholar
• Adeghate E, Fehér E, Kalász H. Evaluating the Phase II drugs currently under investigation for diabetic neuropathy. Expert Opin Investig Drugs 2015;24(1):1-15
   PubMed Web of Science ®Google Scholar
• Schunk S, Linz K, Hinze C, et al. Discovery of a potent analgesic NOP and opioid receptor agonist: cebranopadol. ACS Med Chem Lett 2014;5(8):857-62
   PubMed Web of Science ®Google Scholar
• Grünenthal GmbH; Forest Laboratories. Assessment of GRT6005 in painful osteoarthritis of the knee. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD). 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01357837 NLM Identifier: NCT01357837 [Cited 05 March 2015]
   Google Scholar
• Grünenthal GmbH; Forest Laboratories. Safety and efficacy study of GRT6005 in patients with osteoarthritis (OA) knee pain. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01709214 NLM Identifier: NCT01709214 [Cited 05 March 2015]
   Google Scholar
• Grünenthal GmbH; Forest Laboratories. Efficacy and safety of GRT6005 in patients with chronic low back pain. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01725087 NLM Identifier: NCT01725087 [Cited 05 March 2015]
   Google Scholar
• Grünenthal GmbH; Forest Laboratories. Safety and efficacy of GRT6005 in pain due to diabetic polyneuropathy. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01347671 NLM Identifier: NCT01347671 [Cited 05 March 2015]
   Google Scholar
• Grünenthal GmbH; Forest Laboratories. Cebranopadol efficacy and safety in diabetic patients suffering from chronic pain caused by damage to the nerves. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01939366 NLM Identifier: NCT01939366 [Cited 05 March 2015]
   Google Scholar
• Grünenthal GmbH. Painful diabetic polyneuropathy trial with a new centrally acting analgesic. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT00878293 NLM Identifier: NCT00878293 [Cited 05 March 2015]
   Google Scholar
• Grünenthal GmbH. Bunionectomy trial with GRT6005. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT00872885 NLM Identifier: NCT00872885 [Cited 05 March 2015]
   Google Scholar
• Grünenthal GmbH; Forest Laboratories. CORAL - cebranopadol versus morphine prolonged-release in patients with chronic moderate to severe pain related to cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01964378 NLM Identifier: NCT01964378 [Cited 05 March 2015]
   Google Scholar
• Grünenthal GmbH. CORAL XT - open-label extension trial of the CORAL trial. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT02031432 NLM Identifier: NCT02031432 [Cited 05 March 2015]
   Google Scholar